A Phase 1/2 interventional study of levonorgestrel in Healthy, sponsored by Agile Therapeutics. Completed. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-23.
Sponsored by Agile Therapeutics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Pharmacokinetics, safety and wearability in two size patches of AG890 over eight weeks will be evaluated.
To evaluate pharmacokinetic (PK) profile, patch wearability (adhesion and skin irritation), and safety of AG890-6.5 and AG890-12.5 TCDS.
Agile Therapeutics is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Evaluate levonorgestrel delivery in AG890-6.5
Drug: levonorgestrel
Evaluate levonorgestrel delivery in AG890-12.5
Drug: levonorgestrel
transdermal contraceptive delivery system
Also known as: patch, transdermal contraceptive delivery system
Levonorgestrel Pharmacokinetic Profile
The percentage of subjects with a minimal LNG level below pre-specified threshold of 175 pg/mL during the study.
Time frame: 8 weeks
Evaluation of Patch Adhesion
Evaluation of worst patch adhesion score for each subject using a 5-point adhesion scale: 0: ≥90% adhered (no lift) 1. ≥75% adhered but \<90% (some edges showing lift) 2. ≥50% adhered but \<75% (half of system lifts off) 3. \<50% (\< half of system lifts off, but undetached) 4. patch completely detached
Time frame: 8 weeks
Evaluation of Irritation at Patch Application Site
Self-reported worst skin irritation score at patch application site for each subject using a 4-point irritation scale: 0: None 1. Mild 2. Moderate 3. Severe
Time frame: 8 weeks
Evaluation of Itching at Patch Application Site
Self-reported worst skin itching at patch application site by subject using a 4-point scale: 0. None 1. Mild 2. Moderate 3. Severe
Time frame: 8 weeks
Cycle Control
Measurement of unscheduled bleeding/spotting days.
Time frame: 8 weeks
| Milestone | AG890-6.5 | AG890-12.5 |
|---|---|---|
| Started | 18 | 18 |
| Completed | 17 | 18 |
| Not completed | 1 | 0 |
The percentage of subjects with a minimal LNG level below pre-specified threshold of 175 pg/mL during the study.
| % of subjects below 175 pg/mL | AG890-6.5 | AG890-12.5 |
|---|---|---|
| Levonorgestrel Pharmacokinetic Profile | 100 | 83.3 |
Evaluation of worst patch adhesion score for each subject using a 5-point adhesion scale: 0: ≥90% adhered (no lift) 1. ≥75% adhered but \<90% (some edges showing lift) 2. ≥50% adhered but \<75% (half of system lifts off) 3. \<50% (\< half of system lifts off, but undetached) 4. patch completely detached
| Score on a scale | AG890-6.5 | AG890-12.5 |
|---|---|---|
| Evaluation of Patch Adhesion | 0.41 ± 1.004 | 0.78 ± 1.517 |
Self-reported worst skin irritation score at patch application site for each subject using a 4-point irritation scale: 0: None 1. Mild 2. Moderate 3. Severe
| Score on a scale | AG890-6.5 | AG890-12.5 |
|---|---|---|
| Evaluation of Irritation at Patch Application Site | 0.11 ± 0.471 | 0.06 ± 0.236 |
Self-reported worst skin itching at patch application site by subject using a 4-point scale: 0. None 1. Mild 2. Moderate 3. Severe
| Score | AG890-6.5 | AG890-12.5 |
|---|---|---|
| Evaluation of Itching at Patch Application Site | 0.33 ± 0.594 | 0.39 ± 0.502 |
Measurement of unscheduled bleeding/spotting days.
| days | AG890-6.5 | AG890-12.5 |
|---|---|---|
| Cycle Control | 8.4 ± 4.81 | 8.3 ± 4.23 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AG890-6.5 | 0/18 (0%) | 0/18 (0%) | 11/18 (61.1%) |
| AG890-12.5 | 0/18 (0%) | 0/18 (0%) | 9/18 (50%) |
| Event | AG890-6.5 | AG890-12.5 |
|---|---|---|
| Nervous system disordersNervous system disorders | 9/18 | 5/18 |
| Reproductive system ad breast disordersReproductive system and breast disorders | 3/18 | 5/18 |
| Metabolism and nutrition disordersMetabolism and nutrition disorders | 2/18 | 2/18 |
| Psychiatric disordersPsychiatric disorders | 1/18 | 2/18 |
| Gastrointestinal DisordersGastrointestinal disorders | 1/18 | 1/18 |
| Immune system disordersImmune system disorders | 1/18 | 0/18 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 1/18 | 0/18 |
Safety population
| Age, Categorical(Participants) | AG890-6.5 | AG890-12.5 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 18 | 18 | 36 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | AG890-6.5 | AG890-12.5 | Total |
|---|---|---|---|
| Mean | 29.83 ± 8.473 | 34.94 ± 6.673 | 32.39 ± 7.951 |
| Sex: Female, Male(Participants) | AG890-6.5 | AG890-12.5 | Total |
|---|---|---|---|
| Female | 18 | 18 | 36 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(Participants) | AG890-6.5 | AG890-12.5 | Total |
|---|---|---|---|
| United States | 18 | 18 | 36 |
No study locations are listed for this record.
Ran from Jul 2012 to primary completion in Sep 2012, 2 months.
Results were first posted in Aug 2017, 4 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levonorgestrel
Agile Therapeutics